Ascendis Pharma A/S Presents Interim Results from COACH Trial on Achondroplasia Treatment
Reuters
Jun 09, 2025
<a href="https://laohu8.com/S/ASND">Ascendis Pharma A/S</a> Presents Interim Results from COACH Trial on Achondroplasia Treatment
Ascendis Pharma A/S has released interim topline data from their Phase 2 COACH Trial, which is evaluating the combination treatment of TransCon CNP and TransCon hGH in children with achondroplasia. The Week 26 data revealed that in the TransCon CNP treatment-naïve cohort, the mean annualized growth velocity (AGV) was 9.14 cm/year, with an improvement in the mean ACH height Z-score of +0.53 over the 26 weeks. For the cohort previously treated with TransCon CNP, the mean AGV was 8.25 cm/year, with a +0.44 improvement in the mean ACH height Z-score over 26 weeks. The trial aims to assess the effect of the combination treatment on linear growth compared to TransCon CNP alone. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.